Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$3.1B |
| 2 |
Intel
INTC
|
+$1.53B |
| 3 |
Salesforce
CRM
|
+$1.14B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$799M |
| 5 |
Mastercard
MA
|
+$787M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Aerospace
GE
|
+$2.22B |
| 2 |
Toronto Dominion Bank
TD
|
+$2.1B |
| 3 |
PNC Financial Services
PNC
|
+$1.84B |
| 4 |
General Motors
GM
|
+$1.41B |
| 5 |
UnitedHealth
UNH
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 16.93% |
| 3 | Consumer Discretionary | 13.35% |
| 4 | Industrials | 12.42% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
AstraZeneca
AZN
$246B
| $71.9M | 0.02% |
+517,727
| New | +$69.7M |
|
302
ICF International
ICFI
$1.61B
| $71.7M | 0.02% |
653,831
| – | – |
|
303
First Advantage
FA
$3.61B
| $69.6M | 0.02% |
4,988,399
| – | – |
|
304
Essent Group
ESNT
$6.14B
| $68.1M | 0.02% |
1,700,000
+900,000
| +113% | +$37.1M |
|
305
PagSeguro Digital
PAGS
$2.4B
| $66.8M | 0.02% |
7,800,000
+4,306,166
| +123% | +$38.5M |
|
|
CCC
306
CCC Intelligent Solutions
CCC
$4.11B
| $65.5M | 0.02% |
7,305,588
-1,499,480
| -17% | -$13.3M |
|
307
Atkore
ATKR
$3.17B
| $65.5M | 0.02% |
466,155
| – | – |
|
|
GTLS
308
DELISTED
Chart Industries
GTLS
| $62.6M | 0.02% |
499,107
-360,594
| -42% | -$46.4M |
|
|
IBTX
309
DELISTED
Independent Bank Group, Inc.
IBTX
| $62.3M | 0.02% |
1,344,599
-1,102,003
| -45% | -$62.6M |
|
310
GSK
GSK
$101B
| $62.3M | 0.02% |
1,751,318
+1,140
| +0.1% | +$39.9K |
|
311
On Holding
ONON
$10.4B
| $61.5M | 0.02% |
1,980,610
| – | – |
|
312
Newmont
NEM
$124B
| $61.3M | 0.02% |
1,250,000
| – | – |
|
|
FISV
313
Fiserv Inc
FISV
$27.4B
| $60.7M | 0.02% |
536,700
| – | – |
|
314
Emerson Electric
EMR
$91.4B
| $59.6M | 0.02% |
684,009
+391
| +0.1% | +$34.2K |
|
315
Denali Therapeutics
DNLI
$4.04B
| $56.9M | 0.02% |
2,468,824
+208,182
| +9% | +$5.73M |
|
316
CrowdStrike
CRWD
$226B
| $55.9M | 0.02% |
1,629,880
-22,917,452
| -93% | -$663M |
|
|
AZUL
317
DELISTED
Azul
AZUL
| $54.1M | 0.02% |
7,570,322
-107,595
| -1% | -$674K |
|
318
Bentley Systems
BSY
$10.8B
| $52.2M | 0.01% |
1,213,743
| – | – |
|
319
Sempra
SRE
$56.2B
| $52.1M | 0.01% |
689,434
+56
| +0% | +$4.3K |
|
|
CHX
320
DELISTED
ChampionX
CHX
| $50.2M | 0.01% |
1,851,762
| – | – |
|
321
Unity
U
$19.6B
| $49.7M | 0.01% |
1,532,815
-138,469
| -8% | -$4.45M |
|
322
Bristol-Myers Squibb
BMY
$130B
| $49.2M | 0.01% |
709,449
| – | – |
|
|
ONT
323
Onterris Inc
ONT
$576M
| $48.6M | 0.01% |
1,361,917
-610,178
| -31% | -$27.6M |
|
|
AZPN
324
DELISTED
Aspen Technology Inc
AZPN
| $48.5M | 0.01% |
211,701
| – | – |
|
|
LTHM
325
DELISTED
Livent Corporation
LTHM
| $48.3M | 0.01% |
2,223,481
+196,328
| +10% | +$4.54M |
|
Similar funds
Capital Research Global Investors's Q1 2023 Portfolio in Review
As of Q1 2023, Capital Research Global Investors held 458 positions worth $350B, up 5.9% from $331B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Capital Research Global Investors's Q1 2023 filing shows 22 new, 178 increased, 161 reduced and 33 closed positions. Its largest new stake was GE HealthCare: 43,443,782 shares worth $3.56B. The largest sale was GE Aerospace, an estimated $2.22B.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Capital Research Global Investors's largest Q1 2023 buy was GE HealthCare: 43,443,782 shares worth $3.56B.
- Capital Research Global Investors added most to Salesforce in Q1 2023, an estimated $1.14B increase.
- Capital Research Global Investors's biggest Q1 2023 reduction was GE Aerospace, cutting an estimated $2.22B.
- Capital Research Global Investors fully exited First Republic Bank in Q1 2023, selling an estimated $346M.
- Capital Research Global Investors's ten largest holdings make up 27% of its $350B portfolio in Q1 2023.
- Capital Research Global Investors opened 22 new positions and closed 33 in Q1 2023.
- Capital Research Global Investors's portfolio value rose 5.9% quarter-over-quarter to $350B.
Based on Capital Research Global Investors's 13F filing for Q1 2023, filed 15 May 2023.